PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.

Abstract Among several genetic alterations involved in the progression of prostate cancer, B cell lymphoma gene number 2 (BCL-2) is an important target molecule in the progression of androgen-independent prostate cancer (AIPC) after androgen ablation or castration. Nevertheless, the molecular mechanism of BCL-2 in prostate cancer progression remains elusive and controversial. In the current review, we discuss the critical role of BCL-2 in the carcinogenesis of prostate cancer with experimental evidences on the BCL-2 molecular networks in AIPC and androgen-dependent prostate cancer (ADPC) and subsequently suggest perspective research targeting BCL-2. Areas covered: This review focused on the molecular implications of BCL-2 in association with other molecules and signaling pathways involved in the progression and carcinogenesis of prostate cancer. Expert opinion: BCL-2 plays a pivotal role in the progression of AIPC than in ADPC since androgen represses BCL-2. BCL-2 acts as a pro-survival molecule in association with androgen-related signaling in the progression of ADPC, while BCL-2 upregulation, PTEN loss, PI3K/AKT phosphorylation and receptor tyrosine kinase (RTK) activation are primarily involved in AIPC. To identify more effective prostate cancer therapy, further mechanistic studies are required with BCL-2 inhibitors in AIPC and ADPC, considering a multi-target therapy against BCL-2 and its related signaling.
PMID
Related Publications

The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.

Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.

Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.

BCL-2 in prostate cancer: a minireview.

Bad expression influences time to androgen escape in prostate cancer.

Authors

Mayor MeshTerms
Keywords

AKT

BCL-2

PTEN

androgen

microRNAs

prostate cancer

Journal Title expert opinion on therapeutic targets
Publication Year Start




PMID- 28816549
OWN - NLM
STAT- MEDLINE
DA  - 20170817
DCOM- 20170904
LR  - 20170904
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Linking)
VI  - 21
IP  - 9
DP  - 2017 Sep
TI  - Implications of Bcl-2 and its interplay with other molecules and signaling
      pathways in prostate cancer progression.
PG  - 911-920
LID - 10.1080/14728222.2017.1369044 [doi]
AB  - INTRODUCTION: Among several genetic alterations involved in the progression of
      prostate cancer, B cell lymphoma gene number 2 (BCL-2) is an important target
      molecule in the progression of androgen-independent prostate cancer (AIPC) after 
      androgen ablation or castration. Nevertheless, the molecular mechanism of BCL-2
      in prostate cancer progression remains elusive and controversial. In the current 
      review, we discuss the critical role of BCL-2 in the carcinogenesis of prostate
      cancer with experimental evidences on the BCL-2 molecular networks in AIPC and
      androgen-dependent prostate cancer (ADPC) and subsequently suggest perspective
      research targeting BCL-2. Areas covered: This review focused on the molecular
      implications of BCL-2 in association with other molecules and signaling pathways 
      involved in the progression and carcinogenesis of prostate cancer. Expert
      opinion: BCL-2 plays a pivotal role in the progression of AIPC than in ADPC since
      androgen represses BCL-2. BCL-2 acts as a pro-survival molecule in association
      with androgen-related signaling in the progression of ADPC, while BCL-2
      upregulation, PTEN loss, PI3K/AKT phosphorylation and receptor tyrosine kinase
      (RTK) activation are primarily involved in AIPC. To identify more effective
      prostate cancer therapy, further mechanistic studies are required with BCL-2
      inhibitors in AIPC and ADPC, considering a multi-target therapy against BCL-2 and
      its related signaling.
FAU - Kim, Ju-Ha
AU  - Kim JH
AD  - a Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine , 
      Kyung Hee University , Seoul , South Korea.
FAU - Lee, Hyemin
AU  - Lee H
AD  - a Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine , 
      Kyung Hee University , Seoul , South Korea.
FAU - Shin, Eun Ah
AU  - Shin EA
AD  - a Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine , 
      Kyung Hee University , Seoul , South Korea.
FAU - Kim, Dong Hee
AU  - Kim DH
AD  - b Department of East West Medical Science, Graduate School of East West Medical
      Science , Kyung Hee University , Yongin , South Korea.
FAU - Choi, Jhin Baek
AU  - Choi JB
AD  - b Department of East West Medical Science, Graduate School of East West Medical
      Science , Kyung Hee University , Yongin , South Korea.
FAU - Kim, Sung-Hoon
AU  - Kim SH
AD  - a Cancer Molecular Targeted Herbal Research Center, College of Korean Medicine , 
      Kyung Hee University , Seoul , South Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170823
PL  - England
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
RN  - 0 (Androgens)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Androgens/*metabolism
MH  - Animals
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/genetics/*pathology
MH  - Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism
MH  - Signal Transduction
MH  - Up-Regulation
OTO - NOTNLM
OT  - AKT
OT  - BCL-2
OT  - PTEN
OT  - androgen
OT  - microRNAs
OT  - prostate cancer
EDAT- 2017/08/18 06:00
MHDA- 2017/09/05 06:00
CRDT- 2017/08/18 06:00
AID - 10.1080/14728222.2017.1369044 [doi]
PST - ppublish
SO  - Expert Opin Ther Targets. 2017 Sep;21(9):911-920. doi:
      10.1080/14728222.2017.1369044. Epub 2017 Aug 23.